Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Non-Current Liabilities: 2020-2025

Historic Other Non-Current Liabilities for UroGen Pharma (URGN) over the last 5 years, with Sep 2025 value amounting to $3.8 million.

  • UroGen Pharma's Other Non-Current Liabilities rose 18.69% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 18.69%. This contributed to the annual value of $3.8 million for FY2024, which is 18.69% up from last year.
  • UroGen Pharma's Other Non-Current Liabilities amounted to $3.8 million in Q3 2025, which was down 0.00% from $3.8 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Other Non-Current Liabilities peaked at $3.8 million during Q4 2024, and registered a low of $2.7 million during Q1 2021.
  • Over the past 3 years, UroGen Pharma's median Other Non-Current Liabilities value was $3.2 million (recorded in 2024), while the average stood at $3.4 million.
  • Data for UroGen Pharma's Other Non-Current Liabilities shows a peak YoY rose of 18.69% (in 2024) over the last 5 years.
  • Over the past 5 years, UroGen Pharma's Other Non-Current Liabilities (Quarterly) stood at $2.8 million in 2021, then grew by 6.19% to $3.0 million in 2022, then grew by 5.83% to $3.2 million in 2023, then climbed by 18.69% to $3.8 million in 2024, then rose by 18.69% to $3.8 million in 2025.
  • Its Other Non-Current Liabilities stands at $3.8 million for Q3 2025, versus $3.8 million for Q2 2025 and $3.8 million for Q1 2025.